DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Canasa (Mesalamine) - Indications and Dosage

 
 



INDICATIONS AND USAGE

CANASA® Suppositories are indicated for the treatment of active ulcerative proctitis.

DOSAGE AND ADMINISTRATION

The usual dosage of CANASA® (mesalamine) Suppositories is one 500 mg rectal suppository 2 times daily with possible increase to 3 times daily if inadequate response at two weeks. The suppository should be retained for one to three hours or longer, if possible, to achieve the maximum benefit. While the effect of CANASA® Suppositories may be seen within three to twenty-one days, the usual course of therapy would be from three to six weeks depending on symptoms and sigmoidoscopic findings. Studies have suggested that CANASA® Suppositories will delay relapse after the six-week short-term treatment.

PATIENT INSTRUCTIONS:

NOTE: CANASA® Suppositories will cause staining of direct contact surfaces, including but not limited to fabrics, flooring, painted surfaces, marble, granite, vinyl, and enamel.

  1. Detach one suppository from strip of suppositories.
  2. Hold suppository upright and carefully remove the plastic wrapper.
  3. Avoid excessive handling of suppository, which is designed to melt at body temperature.
  4. Insert suppository completely into rectum with gentle pressure, pointed end first.
  5. A small amount of lubricating gel may be used on the tip of the suppository to assist insertion.

HOW SUPPLIED

CANASA® Suppositories:    CANASA® Suppositories for rectal administration are available as bullet shaped, light tan suppositories containing 500 mg mesalamine supplied in boxes of 30 individually plastic wrapped suppositories (NDC 58914-500-56).

Boxes of 30.

Store below 25°C, do not freeze. Keep away from direct heat, light or humidity.

Rx only

Axcan Scandipharm Inc.

Birmingham, AL 35242

Date: January 4, 2001

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2012